Pleiotropic actions of IP6K1 mediate hepatic metabolic dysfunction to promote nonalcoholic fatty liver disease and steatohepatitis

[1]  Jun Yu,et al.  O‐GlcNAcylation inhibits hepatic stellate cell activation , 2021, Journal of gastroenterology and hepatology.

[2]  Ryokichi Koyama,et al.  The enzymatic activity of inositol hexakisphosphate kinase controls circulating phosphate in mammals , 2021, Nature Communications.

[3]  S. Friedman,et al.  Mechanisms and disease consequences of nonalcoholic fatty liver disease , 2021, Cell.

[4]  M. Ferrer,et al.  Identification of Small-Molecule Inhibitors of Human Inositol Hexakisphosphate Kinases by High-Throughput Screening. , 2021, ACS pharmacology & translational science.

[5]  Jianhua Zhang,et al.  New Insights Into the Biology of Protein O-GlcNAcylation: Approaches and Observations , 2021, Frontiers in Aging.

[6]  R. Schwabe,et al.  Mechanisms of Fibrosis Development in Nonalcoholic Steatohepatitis , 2020 .

[7]  A. Chakraborty,et al.  Targeting the Inositol Pyrophosphate Biosynthetic Enzymes in Metabolic Diseases , 2020, Molecules.

[8]  B. Neuschwander‐Tetri,et al.  The metabolic basis of nonalcoholic steatohepatitis , 2020, Endocrinology, diabetes & metabolism.

[9]  B. Neuschwander‐Tetri.  Therapeutic landscape for NAFLD in 2020. , 2020, Gastroenterology.

[10]  Chad A. Cowan,et al.  GPR146 Deficiency Protects against Hypercholesterolemia and Atherosclerosis , 2019, Cell.

[11]  Su Jin Lee,et al.  Curcumin Ameliorates Nonalcoholic Fatty Liver Disease through Inhibition of O-GlcNAcylation , 2019, Nutrients.

[12]  Shelly C. Lu,et al.  Hyaluronan synthase 2–mediated hyaluronan production mediates Notch1 activation and liver fibrosis , 2019, Science Translational Medicine.

[13]  Jun Yu,et al.  O-GlcNAc transferase suppresses necroptosis and liver fibrosis , 2019, bioRxiv.

[14]  S. Frye,et al.  Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structure-Activity Analysis. , 2019, Journal of medicinal chemistry.

[15]  G. Shulman,et al.  Emerging Pharmacological Targets for the Treatment of Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Type 2 Diabetes. , 2019, Annual review of pharmacology and toxicology.

[16]  Caroline L. Wilson,et al.  Platelet GPIbα is a mediator and potential interventional target for NASH and subsequent liver cancer , 2019, Nature Medicine.

[17]  B. Neuschwander‐Tetri,et al.  An Inhibitor of Arginine‐Glycine‐Aspartate‐Binding Integrins Reverses Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis , 2018, Hepatology communications.

[18]  Ethan X. Fang,et al.  Adipocyte OGT governs diet-induced hyperphagia and obesity , 2018, Nature Communications.

[19]  Su Jin Lee,et al.  Silibinin Ameliorates O-GlcNAcylation and Inflammation in a Mouse Model of Nonalcoholic Steatohepatitis , 2018, International journal of molecular sciences.

[20]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[21]  S. Frye,et al.  Use of Protein Kinase–Focused Compound Libraries for the Discovery of New Inositol Phosphate Kinase Inhibitors , 2018, SLAS discovery : advancing life sciences R & D.

[22]  A. Chakraborty.  The inositol pyrophosphate pathway in health and diseases , 2018, Biological reviews of the Cambridge Philosophical Society.

[23]  K. Nadeau,et al.  Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. , 2018, Journal of hepatology.

[24]  M. Birnbaum,et al.  Activation of Liver AMPK with PF-06409577 Corrects NAFLD and Lowers Cholesterol in Rodent and Primate Preclinical Models , 2018, EBioMedicine.

[25]  S. Snyder,et al.  Inhibition of IP6K1 suppresses neutrophil-mediated pulmonary damage in bacterial pneumonia , 2018, Science Translational Medicine.

[26]  D. Sheppard,et al.  TGF-β1 Signaling and Tissue Fibrosis. , 2018, Cold Spring Harbor perspectives in biology.

[27]  M. Konerman,et al.  Pharmacotherapy for NASH: Current and emerging. , 2018, Journal of hepatology.

[28]  Jun Yu,et al.  O-GlcNAc transferase promotes fatty liver-associated liver cancer through inducing palmitic acid and activating endoplasmic reticulum stress. , 2017, Journal of hepatology.

[29]  J. Xu,et al.  AMPK: a novel target for treating hepatic fibrosis , 2017, Oncotarget.

[30]  Zhi-xiang Xu,et al.  Focal Adhesion Kinase Regulates Hepatic Stellate Cell Activation and Liver Fibrosis , 2017, Scientific Reports.

[31]  Barbara Sitek,et al.  Identification of the Consistently Altered Metabolic Targets in Human Hepatocellular Carcinoma , 2017, Cellular and molecular gastroenterology and hepatology.

[32]  S. Friedman,et al.  Mechanisms of hepatic stellate cell activation , 2017, Nature Reviews Gastroenterology &Hepatology.

[33]  R. Bhandari,et al.  Inositol Pyrophosphates: Energetic, Omnipresent and Versatile Signalling Molecules , 2017, Journal of the Indian Institute of Science.

[34]  Alfred C. Chin,et al.  Neuronal migration is mediated by inositol hexakisphosphate kinase 1 via α-actinin and focal adhesion kinase , 2017, Proceedings of the National Academy of Sciences.

[35]  R. Tyagi,et al.  Global IP6K1 deletion enhances temperature modulated energy expenditure which reduces carbohydrate and fat induced weight gain , 2016, Molecular metabolism.

[36]  J. Barrow,et al.  Adipocyte-specific deletion of Ip6k1 reduces diet-induced obesity by enhancing AMPK-mediated thermogenesis. , 2016, The Journal of clinical investigation.

[37]  Mi-Sung Kim,et al.  ChREBP regulates fructose-induced glucose production independently of insulin signaling. , 2016, The Journal of clinical investigation.

[38]  R. Tyagi,et al.  Inositol hexakisphosphate kinase-1 interacts with perilipin1 to modulate lipolysis. , 2016, The international journal of biochemistry & cell biology.

[39]  Y. Moritoh,et al.  Inositol Hexakisphosphate Kinase 3 Regulates Metabolism and Lifespan in Mice , 2016, Scientific Reports.

[40]  J. Barrow,et al.  TNP [N2-(m-Trifluorobenzyl), N6-(p-nitrobenzyl)purine] ameliorates diet induced obesity and insulin resistance via inhibition of the IP6K1 pathway , 2016, Molecular metabolism.

[41]  N. Balasubramanian,et al.  Deletion of inositol hexakisphosphate kinase 1 (IP6K1) reduces cell migration and invasion, conferring protection from aerodigestive tract carcinoma in mice , 2016, Cellular signalling.

[42]  D. Fiedler,et al.  Inositol hexakisphosphate kinase 1 (IP6K1) activity is required for cytoplasmic dynein-driven transport , 2016, The Biochemical journal.

[43]  G. Ioannou.  The Role of Cholesterol in the Pathogenesis of NASH , 2016, Trends in Endocrinology & Metabolism.

[44]  J. Colca,et al.  Loss of Mitochondrial Pyruvate Carrier 2 in the Liver Leads to Defects in Gluconeogenesis and Compensation via Pyruvate-Alanine Cycling. , 2015, Cell metabolism.

[45]  O. Gavrilova,et al.  Conditional Knock-out Reveals a Requirement for O-Linked N-Acetylglucosaminase (O-GlcNAcase) in Metabolic Homeostasis* , 2015, The Journal of Biological Chemistry.

[46]  R. Kleemann,et al.  Establishment of a General NAFLD Scoring System for Rodent Models and Comparison to Human Liver Pathology , 2014, PloS one.

[47]  H. Moch,et al.  Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes. , 2014, Cancer cell.

[48]  B. Potter,et al.  The enzymes of human diphosphoinositol polyphosphate metabolism , 2013, The FEBS journal.

[49]  G. Shulman,et al.  Reversal of hypertriglyceridemia, fatty liver disease, and insulin resistance by a liver-targeted mitochondrial uncoupler. , 2013, Cell metabolism.

[50]  Wei Hongshan,et al.  Protein O Glycosylation Regulates Activation of Hepatic Stellate Cells , 2013, Inflammation.

[51]  Wei Hongshan,et al.  Protein O Glycosylation Regulates Activation of Hepatic Stellate Cells , 2013, Inflammation.

[52]  M. Kapoor,et al.  Targeting Focal Adhesion Kinase in Fibrotic Diseases , 2013, BioDrugs.

[53]  A. Saiardi.  How inositol pyrophosphates control cellular phosphate homeostasis? , 2012, Advances in biological regulation.

[54]  A. Saiardi,et al.  Influence of Inositol Pyrophosphates on Cellular Energy Dynamics , 2011, Science.

[55]  G. Hart,et al.  Cross talk between O-GlcNAcylation and phosphorylation: roles in signaling, transcription, and chronic disease. , 2011, Annual review of biochemistry.

[56]  Xiaoyong Yang,et al.  O-GlcNAcylation Increases ChREBP Protein Content and Transcriptional Activity in the Liver , 2011, Diabetes.

[57]  Anutosh Chakraborty,et al.  Inositol Pyrophosphates Inhibit Akt Signaling, Thereby Regulating Insulin Sensitivity and Weight Gain , 2010, Cell.

[58]  S. Shears.  Diphosphoinositol Polyphosphates: Metabolic Messengers? , 2009, Molecular Pharmacology.

[59]  H. Cortez‐Pinto,et al.  Uncoupling proteins and non-alcoholic fatty liver disease. , 2009, Journal of hepatology.

[60]  J. York,et al.  Characterization of a Selective Inhibitor of Inositol Hexakisphosphate Kinases , 2009, Journal of Biological Chemistry.

[61]  S. Snyder,et al.  Gene deletion of inositol hexakisphosphate kinase 1 reveals inositol pyrophosphate regulation of insulin secretion, growth, and spermiogenesis , 2008, Proceedings of the National Academy of Sciences.

[62]  J. Goldstein,et al.  Selective versus total insulin resistance: a pathogenic paradox. , 2008, Cell metabolism.

[63]  A. Saiardi,et al.  Requirement of Inositol Pyrophosphates for Full Exocytotic Capacity in Pancreatic β Cells , 2007, Science.

[64]  J. López-Novoa,et al.  Involvement of H- and N-Ras isoforms in transforming growth factor-beta1-induced proliferation and in collagen and fibronectin synthesis. , 2006, Experimental cell research.

[65]  S. Snyder,et al.  Phosphorylation of Proteins by Inositol Pyrophosphates , 2004, Science.

[66]  B. Lowell,et al.  Obesity‐related fatty liver is unchanged in mice deficient for mitochondrial uncoupling protein 2 , 2002, Hepatology.

[67]  A. Saiardi.  Cell signalling by inositol pyrophosphates. , 2012, Sub-cellular biochemistry.

[68]  F. Schaffner,et al.  Nonalcoholic fatty liver disease. , 1986, Progress in liver diseases.